{"protocolSection": {"identificationModule": {"nctId": "NCT02892344", "orgStudyIdInfo": {"id": "CQVM149B2303"}, "secondaryIdInfos": [{"id": "2016-000472-22", "type": "EUDRACT_NUMBER"}], "organization": {"fullName": "Novartis", "class": "INDUSTRY"}, "briefTitle": "Study of QMF149 (150/80 \u00b5g) Compared With MF Twisthaler\u00ae (200 \u00b5g) in Patients With Asthma", "officialTitle": "A Multi-center, Randomized, 12-week Treatment, Doubleblind Study to Assess the Efficacy and Safety of QMF149 (150/80 Microgram) Compared With MF Twisthaler\u00ae (200 Microgram) in Adult and Adolescent Patients With Asthma"}, "statusModule": {"statusVerifiedDate": "2021-10", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2017-01-16", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2018-11-05", "type": "ACTUAL"}, "completionDateStruct": {"date": "2018-11-30", "type": "ACTUAL"}, "studyFirstSubmitDate": "2016-08-29", "studyFirstSubmitQcDate": "2016-09-01", "studyFirstPostDateStruct": {"date": "2016-09-08", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2019-05-29", "resultsFirstSubmitQcDate": "2019-07-31", "resultsFirstPostDateStruct": {"date": "2019-09-12", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2021-10-07", "lastUpdatePostDateStruct": {"date": "2021-10-11", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Novartis Pharmaceuticals", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": true, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "The purpose of the trial was to evaluate efficacy and safety of QMF149 150/80 microgram o.d.\n\ndelivered via Concept1 compared to MF 200 microgram o.d., delivered via Twisthaler\u00ae in terms of lung function and symptom control in poorly (ie inadequately) controlled asthma patients. This study was to assess contribution of LABA as an add-on therapy to low dose ICS monotherapy.", "detailedDescription": "The primary objective of this study was to demonstrate the superiority of QMF149 150/80 microgram o.d. (in the evening) delivered via Concept1 compared with MF 200 microgram o.d. (in the evening) delivered via Twisthaler\u00ae in terms of trough FEV1 after 12 weeks of treatment in adults and adolescents. The key secondary objective of this study was to demonstrate the superiority of QMF149 150/80 microgram to MF 200 microgram o.d. in terms of ACQ-7 after 12 weeks of treatment."}, "conditionsModule": {"conditions": ["Mild Asthma"], "keywords": ["Phase III, blinded, QMF149, Mometasone furoate (MF), mild asthma, Adolescent, adult"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "TRIPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 802, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "QMF149 150/80 \u03bcg", "type": "EXPERIMENTAL", "description": "QMF149 150/80 microgram o.d. delivered via Concept1", "interventionNames": ["Drug: QMF149 150/80 \u03bcg"]}, {"label": "MF 200 \u00b5g", "type": "ACTIVE_COMPARATOR", "description": "MF 200 microgram o.d. delivered via Twisthaler\u00ae", "interventionNames": ["Drug: MF 200 \u03bcg"]}], "interventions": [{"type": "DRUG", "name": "QMF149 150/80 \u03bcg", "description": "QMF149 150/80 \u03bcg o.d via Concept1", "armGroupLabels": ["QMF149 150/80 \u03bcg"], "otherNames": ["Indacaterol acetate/Mometasone furoate"]}, {"type": "DRUG", "name": "MF 200 \u03bcg", "description": "MF 200 \u03bcg o.d. via Twisthaler\u00ae", "armGroupLabels": ["MF 200 \u00b5g"], "otherNames": ["Mometasone furoate"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Trough FEV1", "description": "demonstrate the superiority of QMF149 150/80 microgram o.d. (in the evening) delivered via Concept1 compared with MF 200 microgram o.d. (in the evening) delivered via Twisthaler\u00ae in terms of trough FEV1 after 12 weeks of treatment in adults and adolescents. Forced Expiratory Volume in 1 second (FEV1) is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation, measured by spirometry.", "timeFrame": "week 12"}], "secondaryOutcomes": [{"measure": "ACQ-7", "description": "ACQ-7 is an asthma control questionnaire (scoring 5 symptoms, FEV1 entered by the investigator and daily rescue bronchodilator use entered by the patient) validated to evaluate different levels of asthma control. the ACQ-7 was used to assess improvements in asthma symptom control. The ACQ-7, a seven-item disease-specific instrument developed and validated to assess asthma control in patients in clinical trials as well as in individuals in clinical practice, was provided to the site. All seven items were then scored on a 7-point Likert scale, with 0 indicating total control and 6 indicating no control. The questions were equally weighted and the total score was the mean of the seven items. The first 6 questions of the ACQ-7 were completed by the patient while the last question (question 7) was completed by the study investigator using spirometry data generated by the spirometry equipment.", "timeFrame": "week 12"}, {"measure": "Trough FEV1 at Day 2", "description": "Forced Expiratory Volume in 1 second (FEV1) is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation, measured through spirometry testing", "timeFrame": "Day 2"}, {"measure": "Pre-dose FEV1 at Week 4", "description": "Pre-dose FEV1 is defined as the mean of -45 min and -15 min FEV1 values pre-evening dose", "timeFrame": "week 4"}, {"measure": "FVC Over 12 Weeks", "description": "FVC is the total amount of air exhaled during the FEV test. Forced Vital Capacity (FVC) and Forced Expiratory Flow between 25% and 75% of FVC (FEF25-75) will be measured", "timeFrame": "week 12"}, {"measure": "PEF Over 4 and 12 Weeks", "description": "Morning and Evening Peak Expiratory Flow Rate (PEF) will be measured. PEF is the peak expiratory flow, the maximum speed of expiration", "timeFrame": "week 12"}, {"measure": "Percentage of Patients With ACQ-7 MID at Week 12", "description": "MID is Minimum Important Difference. ACQ-7 is an asthma control questionnaire (scoring 5 symptoms, FEV1 entered by the investigator and daily rescue bronchodilator use entered by the patient) validated to evaluate different levels of asthma control. Percent of patients achieving the minimal important difference (MID) in ACQ-7 (i.e. at least 0.5 decrease from baseline) will be measured.", "timeFrame": "week 12"}, {"measure": "Daily E-diary Over 12 Weeks", "description": "Percentage of asthma symptoms free days, the percentage of nights without nighttime awakenings, and the percentage of mornings without symptoms on awakening as recorded by daily electronic Diary (e-Diary) over 12 weeks of treatment", "timeFrame": "week 12"}, {"measure": "ACQ-7 at Week 4", "description": "ACQ-7 is an asthma control questionnaire (scoring 5 symptoms, FEV1 entered by the investigator and daily rescue bronchodilator use entered by the patient) validated to evaluate different levels of asthma control", "timeFrame": "week 4"}, {"measure": "Rescue Medication Use Over 12 Weeks", "description": "Rescue salbutamol/albuterol usage (mean daily, nighttime and daytime use) from e-Diary recordings over 12 weeks of treatment", "timeFrame": "week 12"}, {"measure": "Percentage of Rescue Medication Free Days Over 12 Weeks", "description": "Percentage of rescue medication free days over 12 weeks of treatment period", "timeFrame": "week 12"}, {"measure": "Quality of Life Assessed by Asthma Quality of Life Questionnaire AQLQ-S 12", "description": "The AQLQ is a 32-item disease specific questionnaire designed to measure functional impairments in asthma. Patients are asked to score each item on a 7-point scale based on the experience of last 2 weeks. The overall AQLQ score is the mean response to all 32 questions. Therefore, the possible highest score (better) would be 7 and the lowest (worse) would be 1. Changes in scores of 0.5 to 1.0 are considered clinically meaningful; 1.0 to 1.5 as moderate and \\> 1.5 as marked clinically important differences for any individual domain or for the overall summary score.", "timeFrame": "week 12"}, {"measure": "Number of Patients With Asthma Exacerbation Over 12 Weeks", "description": "The exacerbation categories are: mild, moderate, severe and the combination of moderate or severe. Time to first asthma exacerbation by exacerbation category. Annual rate of asthma exacerbations by exacerbation category.", "timeFrame": "Week 12"}, {"measure": "The Number of Asthma Exacerbations (Moderate or Severe) Over the 12 Week Treatment Period", "description": "Annual incidence rate of asthma exacerbation by severity of exacerbation. The number of asthma exacerbation is used to calculate annual incidence rate. A severe asthma exacerbation is SCS (Systemic Corticosteroids) use \u22653 days and hospitalization or emergency department visit (greater than 24 h) or death due to asthma. A moderate asthma exacerbation is SCS use \u22653 days either as an outpatient or in emergency department visits (less than or equal to 24 h). Worsening of asthma not requiring more than 3 days of SCS or hospitalization/emergency room will be considered mild asthma exacerbations", "timeFrame": "Week 12"}, {"measure": "Number of Patients With First Asthma Exacerbations (Moderate or Severe) Over the 12 Week Treatment Period", "description": "The annual rate of asthma exacerbations were analyzed using a generalized linear model.", "timeFrame": "Week 12"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Patients with a documented diagnosis of asthma for a period of at least 3 months prior to Screening Visit\n* Patients who have used low dose ICS , with or without controller (ie, LABA, Leukotriene Receptor Antagonist ) at stable dose for at least 1 month prior to Screening Visit\n* Adult patients who are symptomatic at screening despite treatment with existing therapy.\n\nPatients with ACQ-7 score \u2265 1.5 at Visit 101 and at Visit 102 (inadequately controlled).\n\n* Adolescent patients :\n* If taking only ICS (without LABA) and are symptomatic at screening despite treatment with low doses of ICS. These patients must have ACQ-7 score \u2265 1.5 at Visit 101 and at Visit 102 .\n* If taking ICS (low dose)/ LABA, and have ACQ-7 score \u22651 and \\<1.5 at Visit 101: they must have ACQ-7 score\u22651.5 at Visit 102 ( prior to randomization).\n* Pre-bronchodilator FEV1\u2265 60 % and \\< 90 % of the predicted normal value for the patient after withholding bronchodilators at both Visits 101 and 102\n* Patients who demonstrate an increase in FEV1 of 12% and \u2265 200 mL within 30 minutes after administration of 400 microgram salbutamol/360 microgram albuterol (or equivalent dose) at Visit 101.\n\nExclusion Criteria:\n\n* Patients who have smoked or inhaled tobacco products (including electronic cigarettes) within the 6 month period prior to Visit 1, or who have a smoking history of greater than or equal to 10 pack year.\n* Patients who have had an asthma attack/exacerbation requiring systemic steroids or hospitalization (\\> 24 hours) or emergency room visit (\u2264 24 hours) as follows:\n* For adults: within 6 weeks of Screening Visit. If patients experience an asthma attack/exacerbation requiring systemic steroids or emergency room visit between Visit 1 and Visit 102 they may be re-screened 6 weeks after recovery from the exacerbation\n* For adolescents: Severe asthma attack/exacerbation requiring systemic corticosteroids in the last 6 months, OR hospitalization (\\> 24 hours) due to severe asthma attack/exacerbation requiring systemic corticosteroids in the last 6 months, OR emergency room visit (\u2264 24 hours) due to severe asthma attack/exacerbation requiring systemic corticosteroids within the last 6 months.\n* Patients who ever required intubation for a severe asthma attack/exacerbation\n* Patients with a clinical condition (eg. glaucoma, cataract and fragility fractures) which may be worsened by ICS administration (according to investigator's medical judgment )\n* Patients who have had a respiratory tract infection or asthma worsening within 4 weeks prior to Screening Visit or between Visit 1and Visit 102. Patients may be re-screened 4 weeks after recovery from their respiratory tract infection or asthma worsening.\n* Patients with any chronic conditions affecting the upper respiratory tract (eg. chronic sinusitis) which in the opinion of the investigator may interfere with the study.\n* Patients with a history of chronic lung diseases other than asthma, including (but not limited to) COPD, sarcoidosis, interstitial lung disease, cystic fibrosis, clinically significant bronchiectasis and active tuberculosis.\n* Patients with Type I diabetes or uncontrolled Type II diabetes.\n* Patients with narcolepsy and/or insomnia.\n* Patients on Maintenance Immunotherapy (desensitization) for allergies or less than 3 months prior to Visit 101 or patients on Maintenance Immunotherapy for more than 3 months prior to Visit 101 but expected to change throughout the course of the study.\n* Patients with diagnosed rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption or with known intolerance to lactose or milk products.\n\n  * Patients who use a long acting muscarinic antagonist (LAMA) within 3 months prior to Visit 1.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "12 Years", "maximumAge": "75 Years", "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"locations": [{"facility": "Novartis Investigative Site", "city": "Bulgaria", "country": "Bulgaria"}, {"facility": "Novartis Investigative Site", "city": "Pleven", "zip": "5800", "country": "Bulgaria", "geoPoint": {"lat": 43.41667, "lon": 24.61667}}, {"facility": "Novartis Investigative Site", "city": "Stara Zagora", "zip": "6000", "country": "Bulgaria", "geoPoint": {"lat": 42.43278, "lon": 25.64194}}, {"facility": "Novartis Investigative Site", "city": "Santiago", "state": "Region Metropolitana", "zip": "7500692", "country": "Chile", "geoPoint": {"lat": -33.45694, "lon": -70.64827}}, {"facility": "Novartis Investigative Site", "city": "Santiago", "zip": "8380453", "country": "Chile", "geoPoint": {"lat": -33.45694, "lon": -70.64827}}, {"facility": "Novartis Investigative Site", "city": "Santiago", "country": "Chile", "geoPoint": {"lat": -33.45694, "lon": -70.64827}}, {"facility": "Novartis Investigative Site", "city": "Vina del Mar", "zip": "2520594", "country": "Chile", "geoPoint": {"lat": -33.02457, "lon": -71.55183}}, {"facility": "Novartis Investigative Site", "city": "Medellin", "state": "Antioquia", "zip": "0050010", "country": "Colombia", "geoPoint": {"lat": 6.25184, "lon": -75.56359}}, {"facility": "Novartis Investigative Site", "city": "Bogota", "state": "Cundinamarca", "zip": "110911", "country": "Colombia", "geoPoint": {"lat": 4.60971, "lon": -74.08175}}, {"facility": "Novartis Investigative Site", "city": "Bogota", "country": "Colombia", "geoPoint": {"lat": 4.60971, "lon": -74.08175}}, {"facility": "Novartis Investigative Site", "city": "Bucaramanga", "country": "Colombia", "geoPoint": {"lat": 7.12539, "lon": -73.1198}}, {"facility": "Novartis Investigative Site", "city": "Medellin", "country": "Colombia", "geoPoint": {"lat": 6.25184, "lon": -75.56359}}, {"facility": "Novartis Investigative Site", "city": "Kohtla-Jarve", "zip": "30322", "country": "Estonia", "geoPoint": {"lat": 59.39861, "lon": 27.27306}}, {"facility": "Novartis Investigative Site", "city": "Tallinn", "zip": "13419", "country": "Estonia", "geoPoint": {"lat": 59.43696, "lon": 24.75353}}, {"facility": "Novartis Investigative Site", "city": "Tartu", "zip": "51014", "country": "Estonia", "geoPoint": {"lat": 58.38062, "lon": 26.72509}}, {"facility": "Novartis Investigative Site", "city": "Bad Woerishofen", "zip": "86825", "country": "Germany"}, {"facility": "Novartis Investigative Site", "city": "Berlin", "zip": "10119", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "Novartis Investigative Site", "city": "Bochum", "zip": "44791", "country": "Germany", "geoPoint": {"lat": 51.48165, "lon": 7.21648}}, {"facility": "Novartis Investigative Site", "city": "Darmstadt", "zip": "64283", "country": "Germany", "geoPoint": {"lat": 49.87167, "lon": 8.65027}}, {"facility": "Novartis Investigative Site", "city": "Frankfurt", "zip": "60596", "country": "Germany", "geoPoint": {"lat": 50.11552, "lon": 8.68417}}, {"facility": "Novartis Investigative Site", "city": "Gauting", "zip": "82131", "country": "Germany", "geoPoint": {"lat": 48.06919, "lon": 11.37703}}, {"facility": "Novartis Investigative Site", "city": "Hamburg", "zip": "20354", "country": "Germany", "geoPoint": {"lat": 53.57532, "lon": 10.01534}}, {"facility": "Novartis Investigative Site", "city": "Hannover", "zip": "30173", "country": "Germany", "geoPoint": {"lat": 52.37052, "lon": 9.73322}}, {"facility": "Novartis Investigative Site", "city": "Landsberg", "zip": "86899", "country": "Germany", "geoPoint": {"lat": 51.52698, "lon": 12.16076}}, {"facility": "Novartis Investigative Site", "city": "Leipzig", "zip": "04207", "country": "Germany", "geoPoint": {"lat": 51.33962, "lon": 12.37129}}, {"facility": "Novartis Investigative Site", "city": "Lubeck", "zip": "23552", "country": "Germany", "geoPoint": {"lat": 53.86893, "lon": 10.68729}}, {"facility": "Novartis Investigative Site", "city": "Mainz", "zip": "55131", "country": "Germany", "geoPoint": {"lat": 49.98419, "lon": 8.2791}}, {"facility": "Novartis Investigative Site", "city": "Marburg", "zip": "D-35037", "country": "Germany", "geoPoint": {"lat": 50.80904, "lon": 8.77069}}, {"facility": "Novartis Investigative Site", "city": "Gyor", "state": "HUN", "zip": "9024", "country": "Hungary", "geoPoint": {"lat": 47.68333, "lon": 17.63512}}, {"facility": "Novartis Investigative Site", "city": "Szazhalombatta", "state": "HUN", "zip": "2440", "country": "Hungary", "geoPoint": {"lat": 47.32579, "lon": 18.92141}}, {"facility": "Novartis Investigative Site", "city": "Torokbalint", "state": "Pest", "zip": "2045", "country": "Hungary", "geoPoint": {"lat": 47.42931, "lon": 18.91356}}, {"facility": "Novartis Investigative Site", "city": "Cegled", "zip": "2700", "country": "Hungary", "geoPoint": {"lat": 47.17266, "lon": 19.79952}}, {"facility": "Novartis Investigative Site", "city": "Godollo", "zip": "2100", "country": "Hungary", "geoPoint": {"lat": 47.59657, "lon": 19.35515}}, {"facility": "Novartis Investigative Site", "city": "Szarvas", "zip": "5540", "country": "Hungary", "geoPoint": {"lat": 46.86667, "lon": 20.55}}, {"facility": "Novartis Investigative Site", "city": "Szeged", "zip": "6722", "country": "Hungary", "geoPoint": {"lat": 46.253, "lon": 20.14824}}, {"facility": "Novartis Investigative Site", "city": "Ahmedabad", "state": "Gujarat", "zip": "380 060", "country": "India", "geoPoint": {"lat": 23.02579, "lon": 72.58727}}, {"facility": "Novartis Investigative Site", "city": "Vadodara", "state": "Gujarat", "zip": "390022", "country": "India", "geoPoint": {"lat": 22.29941, "lon": 73.20812}}, {"facility": "Novartis Investigative Site", "city": "Bangalore", "state": "Karnataka", "zip": "560099", "country": "India", "geoPoint": {"lat": 12.97194, "lon": 77.59369}}, {"facility": "Novartis Investigative Site", "city": "Hubli", "state": "Karnataka", "zip": "580022", "country": "India", "geoPoint": {"lat": 15.34776, "lon": 75.13378}}, {"facility": "Novartis Investigative Site", "city": "Mysore", "state": "Karnataka", "zip": "570001", "country": "India", "geoPoint": {"lat": 12.29791, "lon": 76.63925}}, {"facility": "Novartis Investigative Site", "city": "Cherthala", "state": "Kerala", "zip": "688524", "country": "India", "geoPoint": {"lat": 9.68444, "lon": 76.33558}}, {"facility": "Novartis Investigative Site", "city": "Mumbai", "state": "Maharashtra", "zip": "401107", "country": "India", "geoPoint": {"lat": 19.07283, "lon": 72.88261}}, {"facility": "Novartis Investigative Site", "city": "Nagpur", "state": "Maharashtra", "country": "India", "geoPoint": {"lat": 21.14631, "lon": 79.08491}}, {"facility": "Novartis Investigative Site", "city": "Bikaner", "state": "Rajasthan", "zip": "334003", "country": "India", "geoPoint": {"lat": 28.01762, "lon": 73.31495}}, {"facility": "Novartis Investigative Site", "city": "Coimbatore", "state": "Tamil Nadu", "zip": "641 045", "country": "India", "geoPoint": {"lat": 11.00555, "lon": 76.96612}}, {"facility": "Novartis Investigative Site", "city": "Hyderabad", "state": "Telangana", "zip": "500018", "country": "India", "geoPoint": {"lat": 17.38405, "lon": 78.45636}}, {"facility": "Novartis Investigative Site", "city": "Varanasi", "state": "Uttar Pradesh", "zip": "221005", "country": "India", "geoPoint": {"lat": 25.31668, "lon": 83.01041}}, {"facility": "Novartis Investigative Site", "city": "Cassano delle Murge", "state": "BA", "zip": "70020", "country": "Italy", "geoPoint": {"lat": 40.89112, "lon": 16.76531}}, {"facility": "Novartis Investigative Site", "city": "Firenze", "state": "FI", "zip": "50134", "country": "Italy", "geoPoint": {"lat": 43.77925, "lon": 11.24626}}, {"facility": "Novartis Investigative Site", "city": "Fiumicino", "state": "RM", "zip": "00054", "country": "Italy", "geoPoint": {"lat": 41.77093, "lon": 12.23662}}, {"facility": "Novartis Investigative Site", "city": "Genova", "zip": "16147", "country": "Italy", "geoPoint": {"lat": 44.40478, "lon": 8.94438}}, {"facility": "Novartis Investigative Site", "city": "Roma", "zip": "00161", "country": "Italy", "geoPoint": {"lat": 41.89193, "lon": 12.51133}}, {"facility": "Novartis Investigative Site", "city": "Chuo ku", "state": "Tokyo", "zip": "103 0027", "country": "Japan", "geoPoint": {"lat": 35.57779, "lon": 139.71685}}, {"facility": "Novartis Investigative Site", "city": "Chuo-ku", "state": "Tokyo", "zip": "103-0027", "country": "Japan", "geoPoint": {"lat": 35.57779, "lon": 139.71685}}, {"facility": "Novartis Investigative Site", "city": "Setagaya-ku", "state": "Tokyo", "zip": "157006", "country": "Japan", "geoPoint": {"lat": 35.64825, "lon": 139.65376}}, {"facility": "Novartis Investigative Site", "city": "Shinjuku-ku", "state": "Tokyo", "zip": "162-0053", "country": "Japan", "geoPoint": {"lat": 35.2946, "lon": 139.57059}}, {"facility": "Novartis Investigative Site", "city": "Toshima-ku", "state": "Tokyo", "zip": "171-0014", "country": "Japan"}, {"facility": "Novartis Investigative Site", "city": "Anyang si", "state": "Gyeonggi Do", "zip": "14068", "country": "Korea, Republic of", "geoPoint": {"lat": 37.3925, "lon": 126.92694}}, {"facility": "Novartis Investigative Site", "city": "Hwaseong si", "state": "Gyeonggi Do", "zip": "18450", "country": "Korea, Republic of", "geoPoint": {"lat": 37.20682, "lon": 126.8169}}, {"facility": "Novartis Investigative Site", "city": "Suwon si", "state": "Gyeonggi Do", "zip": "16499", "country": "Korea, Republic of", "geoPoint": {"lat": 37.29111, "lon": 127.00889}}, {"facility": "Novartis Investigative Site", "city": "Bucheon-Si", "state": "Gyeonggi-Do", "zip": "14584", "country": "Korea, Republic of", "geoPoint": {"lat": 37.49889, "lon": 126.78306}}, {"facility": "Novartis Investigative Site", "city": "Seoul", "state": "Korea", "zip": "03312", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Novartis Investigative Site", "city": "Seoul", "state": "Seocho Gu", "zip": "06591", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Novartis Investigative Site", "city": "Busan", "zip": "612-896", "country": "Korea, Republic of", "geoPoint": {"lat": 35.10278, "lon": 129.04028}}, {"facility": "Novartis Investigative Site", "city": "Seoul", "zip": "02841", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Novartis Investigative Site", "city": "Jurmala", "state": "LVA", "zip": "LV-2015", "country": "Latvia", "geoPoint": {"lat": 56.968, "lon": 23.77038}}, {"facility": "Novartis Investigative Site", "city": "Riga", "state": "LV", "zip": "1011", "country": "Latvia", "geoPoint": {"lat": 56.946, "lon": 24.10589}}, {"facility": "Novartis Investigative Site", "city": "Daugavpils", "zip": "LV-5417", "country": "Latvia", "geoPoint": {"lat": 55.88333, "lon": 26.53333}}, {"facility": "Novartis Investigative Site", "city": "Riga", "zip": "LV 1002", "country": "Latvia", "geoPoint": {"lat": 56.946, "lon": 24.10589}}, {"facility": "Novartis Investigative Site", "city": "Riga", "zip": "LV-1001", "country": "Latvia", "geoPoint": {"lat": 56.946, "lon": 24.10589}}, {"facility": "Novartis Investigative Site", "city": "Riga", "zip": "LV-1004", "country": "Latvia", "geoPoint": {"lat": 56.946, "lon": 24.10589}}, {"facility": "Novartis Investigative Site", "city": "Vilnius", "zip": "8109", "country": "Lithuania", "geoPoint": {"lat": 54.68916, "lon": 25.2798}}, {"facility": "Novartis Investigative Site", "city": "Vilnius", "zip": "LT-08661", "country": "Lithuania", "geoPoint": {"lat": 54.68916, "lon": 25.2798}}, {"facility": "Novartis Investigative Site", "city": "Alor Setar", "state": "Kedah", "zip": "05460", "country": "Malaysia", "geoPoint": {"lat": 6.12104, "lon": 100.36014}}, {"facility": "Novartis Investigative Site", "city": "Taiping", "state": "Perak", "zip": "34000", "country": "Malaysia", "geoPoint": {"lat": 4.85, "lon": 100.73333}}, {"facility": "Novartis Investigative Site", "city": "Kuala Terengganu", "state": "Terengganu", "zip": "20400", "country": "Malaysia", "geoPoint": {"lat": 5.3302, "lon": 103.1408}}, {"facility": "Novartis Investigative Site", "city": "Putrajaya", "zip": "62250", "country": "Malaysia", "geoPoint": {"lat": 2.93527, "lon": 101.69112}}, {"facility": "Novartis Investigative Site", "city": "Santiago de Surco", "state": "Lima", "zip": "33", "country": "Peru", "geoPoint": {"lat": -12.13588, "lon": -77.00742}}, {"facility": "Novartis Investigative Site", "city": "Cusco", "zip": "84", "country": "Peru", "geoPoint": {"lat": -13.52264, "lon": -71.96734}}, {"facility": "Novartis Investigative Site", "city": "Lima", "zip": "10", "country": "Peru", "geoPoint": {"lat": -12.04318, "lon": -77.02824}}, {"facility": "Novartis Investigative Site", "city": "Lima", "zip": "14", "country": "Peru", "geoPoint": {"lat": -12.04318, "lon": -77.02824}}, {"facility": "Novartis Investigative Site", "city": "Piura", "zip": "2000", "country": "Peru", "geoPoint": {"lat": -5.19449, "lon": -80.63282}}, {"facility": "Novartis Investigative Site", "city": "Iloilo city", "state": "Iloilo", "zip": "5000", "country": "Philippines", "geoPoint": {"lat": 10.69694, "lon": 122.56444}}, {"facility": "Novartis Investigative Site", "city": "Manila", "zip": "1008", "country": "Philippines", "geoPoint": {"lat": 14.6042, "lon": 120.9822}}, {"facility": "Novartis Investigative Site", "city": "Quezon City", "zip": "1100", "country": "Philippines", "geoPoint": {"lat": 14.6488, "lon": 121.0509}}, {"facility": "Novartis Investigative Site", "city": "Bialystok", "zip": "15-044", "country": "Poland", "geoPoint": {"lat": 53.13333, "lon": 23.16433}}, {"facility": "Novartis Investigative Site", "city": "Biaystok", "zip": "15-430", "country": "Poland"}, {"facility": "Novartis Investigative Site", "city": "Grudziadz", "zip": "86-300", "country": "Poland", "geoPoint": {"lat": 53.48411, "lon": 18.75366}}, {"facility": "Novartis Investigative Site", "city": "Katowice", "zip": "40 085", "country": "Poland", "geoPoint": {"lat": 50.25841, "lon": 19.02754}}, {"facility": "Novartis Investigative Site", "city": "Ekaterinburg", "zip": "620028", "country": "Russian Federation", "geoPoint": {"lat": 56.8519, "lon": 60.6122}}, {"facility": "Novartis Investigative Site", "city": "Moscow", "zip": "115478", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "Novartis Investigative Site", "city": "Rostov-on-Don", "zip": "344011", "country": "Russian Federation", "geoPoint": {"lat": 47.23135, "lon": 39.72328}}, {"facility": "Novartis Investigative Site", "city": "Saint-Petersburg", "zip": "194044", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Novartis Investigative Site", "city": "St Petersburg", "zip": "191015", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Novartis Investigative Site", "city": "St.Petersburg", "zip": "196240", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Novartis Investigative Site", "city": "Bardejov", "state": "Slovak Republic", "zip": "085 01", "country": "Slovakia", "geoPoint": {"lat": 49.29175, "lon": 21.27271}}, {"facility": "Novartis Investigative Site", "city": "Bojnice", "state": "Slovak Republic", "zip": "972 01", "country": "Slovakia", "geoPoint": {"lat": 48.78511, "lon": 18.5864}}, {"facility": "Novartis Investigative Site", "city": "Humenne", "state": "Slovak Republic", "zip": "066 01", "country": "Slovakia", "geoPoint": {"lat": 48.93707, "lon": 21.91625}}, {"facility": "Novartis Investigative Site", "city": "Liptovsky Hradok", "state": "Slovak Republic", "zip": "033 01", "country": "Slovakia", "geoPoint": {"lat": 49.03962, "lon": 19.72335}}, {"facility": "Novartis Investigative Site", "city": "Spisska Nova Ves", "state": "Slovak Republic", "zip": "052 01", "country": "Slovakia", "geoPoint": {"lat": 48.94464, "lon": 20.56153}}, {"facility": "Novartis Investigative Site", "city": "Stropkov", "state": "Slovak Republic", "zip": "09101", "country": "Slovakia", "geoPoint": {"lat": 49.20211, "lon": 21.65216}}, {"facility": "Novartis Investigative Site", "city": "Banska Bystrica", "state": "SVK", "zip": "974 05", "country": "Slovakia", "geoPoint": {"lat": 48.73946, "lon": 19.15349}}, {"facility": "Novartis Investigative Site", "city": "Poprad", "state": "SVK", "zip": "058 01", "country": "Slovakia", "geoPoint": {"lat": 49.06144, "lon": 20.29798}}, {"facility": "Novartis Investigative Site", "city": "Bratislava", "zip": "841 04", "country": "Slovakia", "geoPoint": {"lat": 48.14816, "lon": 17.10674}}, {"facility": "Novartis Investigative Site", "city": "Cadca", "zip": "022 01", "country": "Slovakia", "geoPoint": {"lat": 49.43503, "lon": 18.78895}}, {"facility": "Novartis Investigative Site", "city": "Presov", "zip": "080 01", "country": "Slovakia", "geoPoint": {"lat": 48.99839, "lon": 21.23393}}, {"facility": "Novartis Investigative Site", "city": "Sabinov", "zip": "08301", "country": "Slovakia", "geoPoint": {"lat": 49.10309, "lon": 21.0988}}, {"facility": "Novartis Investigative Site", "city": "Zvolen", "zip": "960 01", "country": "Slovakia", "geoPoint": {"lat": 48.57442, "lon": 19.15324}}, {"facility": "Novartis Investigative Site", "city": "Brandfort", "state": "Free State", "zip": "8340", "country": "South Africa", "geoPoint": {"lat": -28.70008, "lon": 26.45968}}, {"facility": "Novartis Investigative Site", "city": "Middelburg", "state": "Mpumalanga", "zip": "1050", "country": "South Africa", "geoPoint": {"lat": -25.77507, "lon": 29.46482}}, {"facility": "Novartis Investigative Site", "city": "Cape Town", "state": "ZAF", "zip": "7570", "country": "South Africa", "geoPoint": {"lat": -33.92584, "lon": 18.42322}}, {"facility": "Novartis Investigative Site", "city": "Belleville", "zip": "7530", "country": "South Africa"}, {"facility": "Novartis Investigative Site", "city": "Cape Town", "zip": "7531", "country": "South Africa", "geoPoint": {"lat": -33.92584, "lon": 18.42322}}, {"facility": "Novartis Investigative Site", "city": "Panorama", "zip": "7550", "country": "South Africa", "geoPoint": {"lat": -25.61314, "lon": 30.52899}}, {"facility": "Novartis Investigative Site", "city": "Linkoping", "state": "Ostergotlands Lan", "zip": "587 58", "country": "Sweden", "geoPoint": {"lat": 58.41086, "lon": 15.62157}}, {"facility": "Novartis Investigative Site", "city": "Stockholm", "zip": "111 57", "country": "Sweden", "geoPoint": {"lat": 59.33258, "lon": 18.0649}}, {"facility": "Novartis Investigative Site", "city": "Uppsala", "zip": "75237", "country": "Sweden", "geoPoint": {"lat": 59.85882, "lon": 17.63889}}, {"facility": "Novartis Investigative Site", "city": "Khon Kaen", "state": "THA", "zip": "40002", "country": "Thailand", "geoPoint": {"lat": 16.44671, "lon": 102.833}}, {"facility": "Novartis Investigative Site", "city": "Bangkok", "zip": "10400", "country": "Thailand", "geoPoint": {"lat": 13.75398, "lon": 100.50144}}, {"facility": "Novartis Investigative Site", "city": "Chiang Mai", "zip": "50200", "country": "Thailand", "geoPoint": {"lat": 18.79038, "lon": 98.98468}}, {"facility": "Novartis Investigative Site", "city": "Ho Chi Minh", "state": "VNM", "zip": "700000", "country": "Vietnam", "geoPoint": {"lat": 10.82302, "lon": 106.62965}}, {"facility": "Novartis Investigative Site", "city": "Hai Phong", "zip": "180000", "country": "Vietnam", "geoPoint": {"lat": 20.86481, "lon": 106.68345}}]}, "referencesModule": {"seeAlsoLinks": [{"label": "A Plain Language Trial Summary is available on novartisclinicaltrials.com", "url": "https://www.novctrd.com/ctrdweb/patientsummary/patientsummaries?patientSummaryId=730"}]}, "ipdSharingStatementModule": {"ipdSharing": "UNDECIDED", "description": "Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.\n\nThis trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "QMF149 150/80 \u03bcg", "description": "QMF149 150/80 microgram o.d. delivered via Concept1"}, {"id": "FG001", "title": "MF 200 \u00b5g", "description": "MF 200 microgram o.d. delivered via Twisthaler\u00ae"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "398"}, {"groupId": "FG001", "numSubjects": "404"}]}, {"type": "Full Analysis Set", "achievements": [{"groupId": "FG000", "numSubjects": "395"}, {"groupId": "FG001", "numSubjects": "399"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "394"}, {"groupId": "FG001", "numSubjects": "383"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "21"}]}], "dropWithdraws": [{"type": "Protocol deviation", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "4"}]}, {"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "8"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Non-compliance with study treatment", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Physician Decision", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Subject/guardian decision", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "4"}]}, {"type": "Technical problems", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "QMF149 150/80 \u03bcg", "description": "QMF149 150/80 microgram o.d. delivered via Concept1"}, {"id": "BG001", "title": "MF 200 \u00b5g", "description": "MF 200 microgram o.d. delivered via Twisthaler\u00ae"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "398"}, {"groupId": "BG001", "value": "404"}, {"groupId": "BG002", "value": "802"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "46.1", "spread": "16.26"}, {"groupId": "BG001", "value": "45.1", "spread": "16.27"}, {"groupId": "BG002", "value": "45.6", "spread": "16.26"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "247"}, {"groupId": "BG001", "value": "241"}, {"groupId": "BG002", "value": "488"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "151"}, {"groupId": "BG001", "value": "163"}, {"groupId": "BG002", "value": "314"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "98"}, {"groupId": "BG001", "value": "101"}, {"groupId": "BG002", "value": "199"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "6"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "262"}, {"groupId": "BG001", "value": "265"}, {"groupId": "BG002", "value": "527"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "37"}, {"groupId": "BG001", "value": "33"}, {"groupId": "BG002", "value": "70"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Trough FEV1", "description": "demonstrate the superiority of QMF149 150/80 microgram o.d. (in the evening) delivered via Concept1 compared with MF 200 microgram o.d. (in the evening) delivered via Twisthaler\u00ae in terms of trough FEV1 after 12 weeks of treatment in adults and adolescents. Forced Expiratory Volume in 1 second (FEV1) is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation, measured by spirometry.", "populationDescription": "The Full Analysis Set (FAS) consisted of all patients in the RAN set who received at least one dose of study treatment. Following the intent-to-treat principle, patients were analyzed according to the treatment they were assigned to at randomization. The FAS was used in the analysis of all efficacy variables.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liters", "timeFrame": "week 12", "groups": [{"id": "OG000", "title": "QMF149 150/80 \u03bcg", "description": "QMF149 150/80 microgram o.d. delivered via Concept1"}, {"id": "OG001", "title": "MF 200 \u00b5g", "description": "MF 200 microgram o.d. delivered via Twisthaler\u00ae"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "395"}, {"groupId": "OG001", "value": "399"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.562", "spread": "0.0134"}, {"groupId": "OG001", "value": "2.379", "spread": "0.0134"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Net)", "paramValue": "0.182", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.148", "ciUpperLimit": "0.217"}]}, {"type": "SECONDARY", "title": "ACQ-7", "description": "ACQ-7 is an asthma control questionnaire (scoring 5 symptoms, FEV1 entered by the investigator and daily rescue bronchodilator use entered by the patient) validated to evaluate different levels of asthma control. the ACQ-7 was used to assess improvements in asthma symptom control. The ACQ-7, a seven-item disease-specific instrument developed and validated to assess asthma control in patients in clinical trials as well as in individuals in clinical practice, was provided to the site. All seven items were then scored on a 7-point Likert scale, with 0 indicating total control and 6 indicating no control. The questions were equally weighted and the total score was the mean of the seven items. The first 6 questions of the ACQ-7 were completed by the patient while the last question (question 7) was completed by the study investigator using spirometry data generated by the spirometry equipment.", "populationDescription": "The Full Analysis Set (FAS) consisted of all patients in the RAN set who received at least one dose of study treatment. Following the intent-to-treat principle, patients were analyzed according to the treatment they were assigned to at randomization. The FAS was used in the analysis of all efficacy variables.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Units on a scale", "timeFrame": "week 12", "groups": [{"id": "OG000", "title": "QMF149 150/80 \u03bcg", "description": "QMF149 150/80 microgram o.d. delivered via Concept1"}, {"id": "OG001", "title": "MF 200 \u00b5g", "description": "MF 200 microgram o.d. delivered via Twisthaler\u00ae"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "395"}, {"groupId": "OG001", "value": "399"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.323", "spread": "0.0411"}, {"groupId": "OG001", "value": "1.540", "spread": "0.0411"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Net)", "paramValue": "-0.218", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.293", "ciUpperLimit": "-0.143"}]}, {"type": "SECONDARY", "title": "Trough FEV1 at Day 2", "description": "Forced Expiratory Volume in 1 second (FEV1) is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation, measured through spirometry testing", "populationDescription": "The Full Analysis Set (FAS) consisted of all patients in the RAN set who received at least one dose of study treatment. Following the intent-to-treat principle, patients were analyzed according to the treatment they were assigned to at randomization. The FAS was used in the analysis of all efficacy variables", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liters", "timeFrame": "Day 2", "groups": [{"id": "OG000", "title": "QMF149 150/80 \u03bcg", "description": "QMF149 150/80 microgram o.d. delivered via Concept1"}, {"id": "OG001", "title": "MF 200 \u00b5g", "description": "MF 200 microgram o.d. delivered via Twisthaler\u00ae"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "395"}, {"groupId": "OG001", "value": "399"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.490", "spread": "0.0108"}, {"groupId": "OG001", "value": "2.358", "spread": "0.0108"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Net)", "paramValue": "0.132", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.105", "ciUpperLimit": "0.158"}]}, {"type": "SECONDARY", "title": "Pre-dose FEV1 at Week 4", "description": "Pre-dose FEV1 is defined as the mean of -45 min and -15 min FEV1 values pre-evening dose", "populationDescription": "The Full Analysis Set (FAS) consisted of all patients in the RAN set who received at least one dose of study treatment. Following the intent-to-treat principle, patients were analyzed according to the treatment they were assigned to at randomization. The FAS was used in the analysis of all efficacy variables", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liters", "timeFrame": "week 4", "groups": [{"id": "OG000", "title": "QMF149 150/80 \u03bcg", "description": "QMF149 150/80 microgram o.d. delivered via Concept1"}, {"id": "OG001", "title": "MF 200 \u00b5g", "description": "MF 200 microgram o.d. delivered via Twisthaler\u00ae"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "395"}, {"groupId": "OG001", "value": "399"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.545", "spread": "0.0132"}, {"groupId": "OG001", "value": "2.369", "spread": "0.0131"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Net)", "paramValue": "0.176", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.145", "ciUpperLimit": "0.207"}]}, {"type": "SECONDARY", "title": "FVC Over 12 Weeks", "description": "FVC is the total amount of air exhaled during the FEV test. Forced Vital Capacity (FVC) and Forced Expiratory Flow between 25% and 75% of FVC (FEF25-75) will be measured", "populationDescription": "The Full Analysis Set (FAS) consisted of all patients in the RAN set who received at least one dose of study treatment. Following the intent-to-treat principle, patients were analyzed according to the treatment they were assigned to at randomization. The FAS was used in the analysis of all efficacy variables", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liters", "timeFrame": "week 12", "groups": [{"id": "OG000", "title": "QMF149 150/80 \u03bcg", "description": "QMF149 150/80 microgram o.d. delivered via Concept1"}, {"id": "OG001", "title": "MF 200 \u00b5g", "description": "MF 200 microgram o.d. delivered via Twisthaler\u00ae"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "395"}, {"groupId": "OG001", "value": "399"}]}], "classes": [{"title": "Pre dose trough FVC (n=383,379)", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "383"}, {"groupId": "OG001", "value": "379"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "3.453", "spread": "0.0169"}, {"groupId": "OG001", "value": "3.353", "spread": "0.0169"}]}]}, {"title": "Pre-dose trough FEF25-75% (n=383,379)", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "383"}, {"groupId": "OG001", "value": "379"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.030", "spread": "0.0228"}, {"groupId": "OG001", "value": "1.742", "spread": "0.0228"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Pre-dose trough FVC", "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Net)", "paramValue": "0.100", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.061", "ciUpperLimit": "0.139"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Pre-dose trough FEF25-75%", "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Net)", "paramValue": "0.288", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.231", "ciUpperLimit": "0.345"}]}, {"type": "SECONDARY", "title": "PEF Over 4 and 12 Weeks", "description": "Morning and Evening Peak Expiratory Flow Rate (PEF) will be measured. PEF is the peak expiratory flow, the maximum speed of expiration", "populationDescription": "The Full Analysis Set (FAS) consisted of all patients in the RAN set who received at least one dose of study treatment. Following the intent-to-treat principle, patients were analyzed according to the treatment they were assigned to at randomization. The FAS was used in the analysis of all efficacy variables", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "L/min", "timeFrame": "week 12", "groups": [{"id": "OG000", "title": "QMF149 150/80 \u03bcg", "description": "QMF149 150/80 microgram o.d. delivered via Concept1"}, {"id": "OG001", "title": "MF 200 \u00b5g", "description": "MF 200 microgram o.d. delivered via Twisthaler\u00ae"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "395"}, {"groupId": "OG001", "value": "399"}]}], "classes": [{"title": "Mean Morning PEF (n=382,382)", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "382"}, {"groupId": "OG001", "value": "382"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "31.0", "spread": "1.98"}, {"groupId": "OG001", "value": "3.8", "spread": "1.97"}]}]}, {"title": "Mean Evening PEF (n=386,386)", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "386"}, {"groupId": "OG001", "value": "386"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "26.8", "spread": "1.84"}, {"groupId": "OG001", "value": "0.7", "spread": "1.84"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Mean Morning PEF", "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Net)", "paramValue": "27.2", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "22.1", "ciUpperLimit": "32.4"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Mean Evening PEF", "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Net)", "paramValue": "26.1", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "21.0", "ciUpperLimit": "31.2"}]}, {"type": "SECONDARY", "title": "Percentage of Patients With ACQ-7 MID at Week 12", "description": "MID is Minimum Important Difference. ACQ-7 is an asthma control questionnaire (scoring 5 symptoms, FEV1 entered by the investigator and daily rescue bronchodilator use entered by the patient) validated to evaluate different levels of asthma control. Percent of patients achieving the minimal important difference (MID) in ACQ-7 (i.e. at least 0.5 decrease from baseline) will be measured.", "populationDescription": "The Full Analysis Set (FAS) consisted of all patients in the RAN set who received at least one dose of study treatment. Following the intent-to-treat principle, patients were analyzed according to the treatment they were assigned to at randomization. The FAS was used in the analysis of all efficacy variables", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage", "timeFrame": "week 12", "groups": [{"id": "OG000", "title": "QMF149 150/80 \u03bcg", "description": "QMF149 150/80 microgram o.d. delivered via Concept1"}, {"id": "OG001", "title": "MF 200 \u00b5g", "description": "MF 200 microgram o.d. delivered via Twisthaler\u00ae"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "395"}, {"groupId": "OG001", "value": "399"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "74.7"}, {"groupId": "OG001", "value": "64.9"}]}]}]}, {"type": "SECONDARY", "title": "Daily E-diary Over 12 Weeks", "description": "Percentage of asthma symptoms free days, the percentage of nights without nighttime awakenings, and the percentage of mornings without symptoms on awakening as recorded by daily electronic Diary (e-Diary) over 12 weeks of treatment", "populationDescription": "The Full Analysis Set (FAS) consisted of all patients in the RAN set who received at least one dose of study treatment. Following the intent-to-treat principle, patients were analyzed according to the treatment they were assigned to at randomization. The FAS was used in the analysis of all efficacy variables", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Percentage", "timeFrame": "week 12", "groups": [{"id": "OG000", "title": "QMF149 150/80 \u03bcg", "description": "QMF149 150/80 microgram o.d. delivered via Concept1"}, {"id": "OG001", "title": "MF 200 \u00b5g", "description": "MF 200 microgram o.d. delivered via Twisthaler\u00ae"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "395"}, {"groupId": "OG001", "value": "399"}]}], "classes": [{"title": "% of nights with no night-time awakenings", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "384"}, {"groupId": "OG001", "value": "384"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "13.4", "spread": "1.37"}, {"groupId": "OG001", "value": "8.7", "spread": "1.36"}]}]}, {"title": "% of mornings with no symptoms on awakening", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "384"}, {"groupId": "OG001", "value": "384"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "14.7", "spread": "1.53"}, {"groupId": "OG001", "value": "11.2", "spread": "1.53"}]}]}, {"title": "% of asthma symptom-free days", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "373"}, {"groupId": "OG001", "value": "380"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "17.1", "spread": "1.68"}, {"groupId": "OG001", "value": "14.4", "spread": "1.65"}]}]}]}, {"type": "SECONDARY", "title": "ACQ-7 at Week 4", "description": "ACQ-7 is an asthma control questionnaire (scoring 5 symptoms, FEV1 entered by the investigator and daily rescue bronchodilator use entered by the patient) validated to evaluate different levels of asthma control", "populationDescription": "The Full Analysis Set (FAS) consisted of all patients in the RAN set who received at least one dose of study treatment. Following the intent-to-treat principle, patients were analyzed according to the treatment they were assigned to at randomization. The FAS was used in the analysis of all efficacy variables", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Units on a scale", "timeFrame": "week 4", "groups": [{"id": "OG000", "title": "QMF149 150/80 \u03bcg", "description": "QMF149 150/80 microgram o.d. delivered via Concept1"}, {"id": "OG001", "title": "MF 200 \u00b5g", "description": "MF 200 microgram o.d. delivered via Twisthaler\u00ae"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "395"}, {"groupId": "OG001", "value": "399"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.454", "spread": "0.0408"}, {"groupId": "OG001", "value": "1.658", "spread": "0.0406"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Net)", "paramValue": "-0.204", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.277", "ciUpperLimit": "-0.131"}]}, {"type": "SECONDARY", "title": "Rescue Medication Use Over 12 Weeks", "description": "Rescue salbutamol/albuterol usage (mean daily, nighttime and daytime use) from e-Diary recordings over 12 weeks of treatment", "populationDescription": "The Full Analysis Set (FAS) consisted of all patients in the RAN set who received at least one dose of study treatment. Following the intent-to-treat principle, patients were analyzed according to the treatment they were assigned to at randomization. The FAS was used in the analysis of all efficacy variables", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Number of puffs of rescue medication", "timeFrame": "week 12", "groups": [{"id": "OG000", "title": "QMF149 150/80 \u03bcg", "description": "QMF149 150/80 microgram o.d. delivered via Concept1"}, {"id": "OG001", "title": "MF 200 \u00b5g", "description": "MF 200 microgram o.d. delivered via Twisthaler\u00ae"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "395"}, {"groupId": "OG001", "value": "399"}]}], "classes": [{"title": "Night-time number of puffs of rescue medication", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "384"}, {"groupId": "OG001", "value": "384"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.26", "spread": "0.025"}, {"groupId": "OG001", "value": "-0.16", "spread": "0.025"}]}]}, {"title": "Daytime number of puffs of rescue medication", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "388"}, {"groupId": "OG001", "value": "389"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.39", "spread": "0.033"}, {"groupId": "OG001", "value": "-0.24", "spread": "0.032"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Night-time number of puffs of rescue medication", "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Net)", "paramValue": "-0.11", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.16", "ciUpperLimit": "-0.05"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Daytime number of puffs of rescue medication", "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Net)", "paramValue": "-0.15", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.22", "ciUpperLimit": "-0.08"}]}, {"type": "SECONDARY", "title": "Percentage of Rescue Medication Free Days Over 12 Weeks", "description": "Percentage of rescue medication free days over 12 weeks of treatment period", "populationDescription": "The Full Analysis Set (FAS) consisted of all patients in the RAN set who received at least one dose of study treatment. Following the intent-to-treat principle, patients were analyzed according to the treatment they were assigned to at randomization. The FAS was used in the analysis of all efficacy variables", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Percentage", "timeFrame": "week 12", "groups": [{"id": "OG000", "title": "QMF149 150/80 \u03bcg", "description": "QMF149 150/80 microgram o.d. delivered via Concept1"}, {"id": "OG001", "title": "MF 200 \u00b5g", "description": "MF 200 microgram o.d. delivered via Twisthaler\u00ae"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "395"}, {"groupId": "OG001", "value": "399"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "22.2", "spread": "1.81"}, {"groupId": "OG001", "value": "14.1", "spread": "1.80"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Net)", "paramValue": "8.1", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "4.3", "ciUpperLimit": "11.8"}]}, {"type": "SECONDARY", "title": "Quality of Life Assessed by Asthma Quality of Life Questionnaire AQLQ-S 12", "description": "The AQLQ is a 32-item disease specific questionnaire designed to measure functional impairments in asthma. Patients are asked to score each item on a 7-point scale based on the experience of last 2 weeks. The overall AQLQ score is the mean response to all 32 questions. Therefore, the possible highest score (better) would be 7 and the lowest (worse) would be 1. Changes in scores of 0.5 to 1.0 are considered clinically meaningful; 1.0 to 1.5 as moderate and \\> 1.5 as marked clinically important differences for any individual domain or for the overall summary score.", "populationDescription": "The Full Analysis Set (FAS) consisted of all patients in the RAN set who received at least one dose of study treatment. Following the intent-to-treat principle, patients were analyzed according to the treatment they were assigned to at randomization. The FAS was used in the analysis of all efficacy variables", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Score", "timeFrame": "week 12", "groups": [{"id": "OG000", "title": "QMF149 150/80 \u03bcg", "description": "QMF149 150/80 microgram o.d. delivered via Concept1"}, {"id": "OG001", "title": "MF 200 \u00b5g", "description": "MF 200 microgram o.d. delivered via Twisthaler\u00ae"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "395"}, {"groupId": "OG001", "value": "399"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "5.779", "spread": "0.0475"}, {"groupId": "OG001", "value": "5.630", "spread": "0.0473"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Net)", "paramValue": "0.149", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.064", "ciUpperLimit": "0.234"}]}, {"type": "SECONDARY", "title": "Number of Patients With Asthma Exacerbation Over 12 Weeks", "description": "The exacerbation categories are: mild, moderate, severe and the combination of moderate or severe. Time to first asthma exacerbation by exacerbation category. Annual rate of asthma exacerbations by exacerbation category.", "populationDescription": "The Full Analysis Set (FAS) consisted of all patients in the RAN set who received at least one dose of study treatment. Following the intent-to-treat principle, patients were analyzed according to the treatment they were assigned to at randomization. The FAS was used in the analysis of all efficacy variables", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Number of patients", "timeFrame": "Week 12", "groups": [{"id": "OG000", "title": "QMF149 150/80 \u03bcg", "description": "QMF149 150/80 microgram o.d. delivered via Concept1"}, {"id": "OG001", "title": "MF 200 \u00b5g", "description": "MF 200 microgram o.d. delivered via Twisthaler\u00ae"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "395"}, {"groupId": "OG001", "value": "399"}]}], "classes": [{"title": "Mild asthma exacerbation", "categories": [{"measurements": [{"groupId": "OG000", "value": "11"}, {"groupId": "OG001", "value": "29"}]}]}, {"title": "Moderate asthma exacerbation", "categories": [{"measurements": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "23"}]}]}, {"title": "Severe asthma exacerbation", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "11"}]}]}, {"title": "Moderate or severe asthma exacerbation", "categories": [{"measurements": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "32"}]}]}]}, {"type": "SECONDARY", "title": "The Number of Asthma Exacerbations (Moderate or Severe) Over the 12 Week Treatment Period", "description": "Annual incidence rate of asthma exacerbation by severity of exacerbation. The number of asthma exacerbation is used to calculate annual incidence rate. A severe asthma exacerbation is SCS (Systemic Corticosteroids) use \u22653 days and hospitalization or emergency department visit (greater than 24 h) or death due to asthma. A moderate asthma exacerbation is SCS use \u22653 days either as an outpatient or in emergency department visits (less than or equal to 24 h). Worsening of asthma not requiring more than 3 days of SCS or hospitalization/emergency room will be considered mild asthma exacerbations", "populationDescription": "The Full Analysis Set (FAS) consisted of all patients in the RAN set who received at least one dose of study treatment. Following the intent-to-treat principle, patients were analyzed according to the treatment they were assigned to at randomization. The FAS was used in the analysis of all efficacy variables", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Number of exacerbation", "timeFrame": "Week 12", "groups": [{"id": "OG000", "title": "QMF149 150/80 \u03bcg", "description": "QMF149 150/80 microgram o.d. delivered via Concept1"}, {"id": "OG001", "title": "MF 200 \u00b5g", "description": "MF 200 microgram o.d. delivered via Twisthaler\u00ae"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "395"}, {"groupId": "OG001", "value": "399"}]}], "classes": [{"title": "Moderate or severe asthma exacerbation", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "394"}, {"groupId": "OG001", "value": "397"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.08"}, {"groupId": "OG001", "value": "0.31"}]}]}, {"title": "All (mild, moderate, severe) asthma exacerbation", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "394"}, {"groupId": "OG001", "value": "397"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.20"}, {"groupId": "OG001", "value": "0.67"}]}]}]}, {"type": "SECONDARY", "title": "Number of Patients With First Asthma Exacerbations (Moderate or Severe) Over the 12 Week Treatment Period", "description": "The annual rate of asthma exacerbations were analyzed using a generalized linear model.", "populationDescription": "The Full Analysis Set (FAS) consisted of all patients in the RAN set who received at least one dose of study treatment. Following the intent-to-treat principle, patients were analyzed according to the treatment they were assigned to at randomization. The FAS was used in the analysis of all efficacy variables", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Count of participants", "timeFrame": "Week 12", "groups": [{"id": "OG000", "title": "QMF149 150/80 \u03bcg", "description": "QMF149 150/80 microgram o.d. delivered via Concept1"}, {"id": "OG001", "title": "MF 200 \u00b5g", "description": "MF 200 microgram o.d. delivered via Twisthaler\u00ae"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "395"}, {"groupId": "OG001", "value": "399"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "32"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "statisticalMethod": "Regression, Cox", "paramType": "Hazard Ratio (HR)", "paramValue": "0.29", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.14", "ciUpperLimit": "0.59"}]}]}, "adverseEventsModule": {"frequencyThreshold": "1", "timeFrame": "12 weeks", "description": "AE additional description", "eventGroups": [{"id": "EG000", "title": "QMF149 150/80", "description": "QMF149 150/80 microgram o.d. delivered via Concept1", "deathsNumAffected": 0, "deathsNumAtRisk": 396, "seriousNumAffected": 5, "seriousNumAtRisk": 396, "otherNumAffected": 69, "otherNumAtRisk": 396}, {"id": "EG001", "title": "MF 200", "description": "MF 200 microgram o.d. delivered via Twisthaler\u00ae", "deathsNumAffected": 0, "deathsNumAtRisk": 399, "seriousNumAffected": 7, "seriousNumAtRisk": 399, "otherNumAffected": 106, "otherNumAtRisk": 399}], "seriousEvents": [{"term": "Appendix disorder", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (21.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 396}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 399}]}, {"term": "Dental cyst", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (21.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 396}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 399}]}, {"term": "Autoimmune hepatitis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA (21.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 396}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 399}]}, {"term": "Abscess oral", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (21.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 396}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 399}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (21.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 396}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 399}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (21.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 396}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 399}]}, {"term": "Viral upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (21.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 396}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 399}]}, {"term": "Ankle fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (21.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 396}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 399}]}, {"term": "Fibula fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (21.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 396}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 399}]}, {"term": "Incisional hernia", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (21.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 396}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 399}]}, {"term": "Tibia fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (21.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 396}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 399}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (21.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 396}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 399}]}, {"term": "Osteoarthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (21.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 396}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 399}]}, {"term": "Prostate cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA (21.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 396}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 399}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (21.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 396}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 399}]}], "otherEvents": [{"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (21.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 396}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 399}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (21.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 396}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 399}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (21.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 17, "numAtRisk": 396}, {"groupId": "EG001", "numAffected": 19, "numAtRisk": 399}]}, {"term": "Pharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (21.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 396}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 399}]}, {"term": "Sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (21.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 396}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 399}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (21.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 396}, {"groupId": "EG001", "numAffected": 10, "numAtRisk": 399}]}, {"term": "Viral upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (21.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 396}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 399}]}, {"term": "Overdose", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (21.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 396}, {"groupId": "EG001", "numAffected": 10, "numAtRisk": 399}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (21.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 396}, {"groupId": "EG001", "numAffected": 9, "numAtRisk": 399}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (21.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 20, "numAtRisk": 396}, {"groupId": "EG001", "numAffected": 60, "numAtRisk": 399}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (21.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 396}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 399}]}, {"term": "Dysphonia", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (21.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 396}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 399}]}, {"term": "Dyspnoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (21.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 396}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 399}]}, {"term": "Rhinitis allergic", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (21.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 396}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 399}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety"}, "pointOfContact": {"title": "Study Director", "organization": "Novartis Pharmaceuticals", "email": "novartis.email@novartis.com", "phone": "862-778-8300"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot", "hasProtocol": true, "hasSap": false, "hasIcf": false, "label": "Study Protocol", "date": "2018-03-20", "uploadDate": "2019-05-29T14:18", "filename": "Prot_000.pdf", "size": 1219280}, {"typeAbbrev": "SAP", "hasProtocol": false, "hasSap": true, "hasIcf": false, "label": "Statistical Analysis Plan", "date": "2019-01-02", "uploadDate": "2019-05-29T14:18", "filename": "SAP_001.pdf", "size": 442289}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000068656", "term": "Mometasone Furoate"}], "ancestors": [{"id": "D000000893", "term": "Anti-Inflammatory Agents"}, {"id": "D000003879", "term": "Dermatologic Agents"}, {"id": "D000018926", "term": "Anti-Allergic Agents"}], "browseLeaves": [{"id": "M290", "name": "Mometasone Furoate", "asFound": "Tea", "relevance": "HIGH"}, {"id": "M4217", "name": "Anti-Inflammatory Agents", "relevance": "LOW"}, {"id": "M7074", "name": "Dermatologic Agents", "relevance": "LOW"}, {"id": "M20962", "name": "Anti-Allergic Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AAll", "name": "Anti-Allergic Agents"}, {"abbrev": "Infl", "name": "Anti-Inflammatory Agents"}, {"abbrev": "Derm", "name": "Dermatologic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}